A detailed history of Citigroup Inc transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Citigroup Inc holds 177,843 shares of HRMY stock, worth $6.88 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
177,843
Previous 161,984 9.79%
Holding current value
$6.88 Million
Previous $4.89 Million 45.37%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$30.0 - $39.95 $475,770 - $633,567
15,859 Added 9.79%
177,843 $7.1 Million
Q2 2024

Aug 12, 2024

SELL
$28.81 - $33.01 $44,540 - $51,033
-1,546 Reduced 0.95%
161,984 $4.89 Million
Q1 2024

May 10, 2024

SELL
$29.93 - $35.06 $104,425 - $122,324
-3,489 Reduced 2.09%
163,530 $5.49 Million
Q4 2023

Feb 09, 2024

BUY
$19.2 - $33.78 $2.74 Million - $4.81 Million
142,537 Added 582.21%
167,019 $5.39 Million
Q3 2023

Nov 09, 2023

SELL
$31.89 - $39.03 $260,445 - $318,758
-8,167 Reduced 25.01%
24,482 $802,000
Q2 2023

Aug 10, 2023

BUY
$30.5 - $37.4 $326,441 - $400,292
10,703 Added 48.77%
32,649 $1.15 Million
Q1 2023

May 11, 2023

SELL
$30.8 - $53.92 $197,582 - $345,896
-6,415 Reduced 22.62%
21,946 $716,000
Q4 2022

Feb 09, 2023

BUY
$45.4 - $60.91 $96,520 - $129,494
2,126 Added 8.1%
28,361 $1.56 Million
Q3 2022

Nov 10, 2022

BUY
$42.06 - $55.45 $250,887 - $330,759
5,965 Added 29.43%
26,235 $1.16 Million
Q2 2022

Aug 10, 2022

SELL
$33.54 - $52.15 $164,413 - $255,639
-4,902 Reduced 19.47%
20,270 $989,000
Q1 2022

May 12, 2022

BUY
$33.14 - $51.13 $133,554 - $206,053
4,030 Added 19.06%
25,172 $1.23 Million
Q4 2021

Feb 10, 2022

BUY
$34.09 - $43.91 $620,812 - $799,645
18,211 Added 621.32%
21,142 $901,000
Q3 2021

Nov 10, 2021

BUY
$25.68 - $38.61 $75,268 - $113,165
2,931 New
2,931 $112,000

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.29B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.